SMA Capital’s Cytokinetics CYTK Stock Holding History

SMA Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.8K	Buy	244 +145	+146%	+$10.4K	0.01%	92
2026 Q1	$6.53K	Buy	+99	New	+$6.29K	﹤0.01%	71

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SMA Capital's CYTK Position: Q2 2026 in Review

SMA Capital increased its Cytokinetics (CYTK) stake by 146% in Q2 2026, buying an estimated $10.4K and bringing the position to 244 shares worth $20.8K. The position accounts for 0.01% of the portfolio, ranked #92.

SMA Capital first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

SMA Capital held 244 shares of Cytokinetics worth $20.8K as of Q2 2026.
SMA Capital bought 145 Cytokinetics shares in Q2 2026, an estimated $10.4K.
Cytokinetics made up 0.01% of SMA Capital's portfolio in Q2 2026, its #92 holding.
SMA Capital first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.